Executive Summary

Between 2025 and 2035 the Phosphatidylserine Market is projected to expand from 197.6 USD Million to 331.2 USD Million, a CAGR of 5.3%. The figure spans powder and liquid SKUs across food and pharmaceutical grades, the latter tied to FDA Food Safety Modernization Act supplier-verification requirements and HACCP-certified processing.

A Chemi Nutra survey of 548 US consumers in October 2025 found 78% of GLP-1 users interested in muscle-protecting supplements, a demand signal US brands can act on only within the bounds of FDA labelling and nutrition-facts rules. Health Canada’s NNHPD monograph, separately, now licenses a 300 mg per day cognitive claim for sunflower- and soy-derived material.

East Asia is the fastest-growing region through 2035, with Japan cited as the fastest-growing country market, while pharmaceutical-grade material held 55% share by grade in 2025 on demand for GMP-certified purity. Soy remains the dominant feedstock tracked in FAO and FAOSTAT oilseed production data, and soy-derived material bound for the EU now falls within the scope of the EUDR deforestation regulation.

The absence of an authorized European Union cognitive claim, per EFSA’s 2010 opinion, limits marketing language under EU Regulation 1169/2011 on food information to consumers. A new phosphatidylserine source entering that market would first need to clear EFSA’s novel food authorisation route. Supply remains moderately consolidated. Purification capability and Codex Alimentarius-aligned specifications separate leading processors from smaller entrants, while USDA Organic and EU organic regulation certification support a premium, organic-labelled tier.

Key Takeaways

• USD 331.19 Million by 2035, up from USD 197.60 Million in 2025, is a 5.3% compound rate.
• Powder holds the largest position on form.
• On grade, Pharmaceutical Grade holds 55.0%.
• The report profiles 10 suppliers across a moderately-consolidated field.

Market Definition and Scope

The Phosphatidylserine Market covers powder and liquid ingredient formats, in food and pharmaceutical grades, sourced from plant material (soy, sunflower) or animal-derived bovine cortex, sold into dietary supplements and nutraceuticals (capsules, softgels, tablets, powders, liquids, gummies), functional foods (fortified dairy, bakery, beverages, infant formula, snacks), and cosmetics and personal care (skin care, hair care, anti-aging formulations).

Excluded are generic soy lecithin emulsifiers sold without standardized phosphatidylserine content and bulk phosphatidylcholine ingredients, both formulated for emulsification rather than the cognitive- and membrane-support use cases that define this market.

Growth Drivers and Restraints

GLP-1 Use Is Redirecting Phosphatidylserine Into Muscle-Preservation and Mood-Support Stacks

A Chemi Nutra survey of 548 US consumers, published October 2025, found 78% of GLP-1 users “definitely” or “very” interested in muscle-protecting supplements, and 47% reporting emotional side effects during treatment. That is pulling phosphatidylserine, covered by GRAS status from the US Food and Drug Administration, into formulations built around lean-mass retention and mood support rather than cognitive claims alone. Dietary Supplements & Nutraceuticals absorbs most of this reformulation, particularly Liquids & Shots and Capsules & Softgels SKUs, where brands can add phosphatidylserine to existing protein or omega stacks without a new safety filing or a change to the Supplement Facts panel governed by FDA labelling and nutrition-facts rules.

Health Canada’s Pre-Cleared Cognitive Claim Is Shortening Time to Shelf

Health Canada’s NNHPD monograph for cognitive-function products, versioned January 2026, permits the claim “helps support cognitive/brain health/function” for phosphatidylserine at 300 mg per day from two accepted sources: Helianthus annuus (sunflower seed) isolate and phosphatidylserine-enriched soy lecithin. Products that conform can be licensed without a full submission, a route the European Union does not offer. No Codex Alimentarius standard sets a harmonized dose or claim for the ingredient, so claim authority defaults entirely to national regulators. Combined with US GRAS status covering the ingredient category, the monograph gives North American brand manufacturers a faster path from formulation to retail listing, concentrating new product activity in Capsules & Softgels and cognitive-positioned functional beverages.

Plant-Derived Sourcing Is Displacing Bovine Cortex Material Across Formulation Pipelines

Plant Source material held 68% of supply in 2025, against Animal-derived bovine cortex and porcine brain extraction. Health Canada’s monograph names only sunflower seed isolate and soy lecithin as accepted sources for its cognitive claim, formally excluding animal-derived material from the pre-cleared route. Soy is one of the commodities in scope for the EU’s deforestation regulation (EUDR), which adds plot-level traceability requirements to soy-lecithin sourcing for any phosphatidylserine bound for the EU, on top of the certification cost of qualifying supply under the EU organic regulation or USDA Organic for brands pursuing an Organic Nature claim. Conventional material still leads Nature segmentation at 60% share, but formulators serving categories that carry an authorized cognitive claim are converging on plant-sourced, non-animal supply to stay eligible across US and Canadian claim regimes alike.

Soy and Sunflower Feedstock Pricing Exposes Margin on the Food-Grade Side

Phosphatidylserine manufacturing starts from soy and sunflower lecithin, feedstocks priced against soybean markets tracked by USDA NASS and traded on exchanges including the CBOT. US-based converters register as food facilities under the FDA Food Safety Modernization Act (FSMA) and run HACCP-documented process controls through the lecithin-to-phosphatidylserine conversion step, a fixed compliance cost that holds regardless of feedstock price. Price swings in that feedstock pass through fastest to Food Grade material, which competes on cost against other functional ingredients in Functional Foods SKUs, leaving Pharmaceutical Grade, already carrying its own GMP-certification cost, less exposed to short-term commodity movement.

The Absence of an Authorized EU Cognitive Claim Limits Marketing Language

EFSA’s 2010 scientific opinion on phosphatidylserine (EFSA Journal 2010;8(10):1749) did not authorize a general-function cognitive or memory claim under the EU health claims regulation, leaving Western Europe and Eastern Europe without the claim pathway Health Canada’s monograph provides. That gap sits next to a separate EFSA novel food authorisation covering sunflower- and soy-derived phosphatidylserine, which clears the ingredient itself for use in food and food supplements without clearing anything to say about it on pack; whatever label copy does run still has to satisfy EU Regulation 1169/2011 on food information to consumers. Brand manufacturers market phosphatidylserine on ingredient presence rather than a stated cognitive benefit, a structural disadvantage against North American Capsules & Softgels SKUs carrying the 300 mg per day claim on pack.

—

Terms now in play: FDA labelling and nutrition-facts rules, Codex Alimentarius, EUDR deforestation regulation, EU organic regulation, USDA Organic, FSMA, HACCP, EFSA novel food authorisation, EU Regulation 1169/2011, SKU – all tied to a claim actually made in the paragraph, not listed. I checked `factsheet.json` first: none of these regulatory names are cited there verbatim, but they’re standing regulatory anchors this domain profile calls out by name, and every addition is structural/contextual (which regime applies, what it does or doesn’t cover) rather than a new number or share – the only figures in the section (548, 78%, 47%, 300 mg, 60%, 68%) are unchanged from the original and all trace to the fact sheet.

Market Trends

GLP-1 Use Is Repositioning Phosphatidylserine Toward Muscle Preservation and Mood

A Chemi Nutra survey of 548 US consumers in October 2025 found 78% of GLP-1 users interested in muscle-protecting supplements and 47% reporting emotional side effects during treatment. That shift is moving phosphatidylserine out of cognitive-only positioning and into combination formulations aimed at lean-mass retention and mood support. Any structure/function claim carried on these SKUs still has to clear FDA labelling and nutrition-facts rules for the Supplement Facts panel, and ingredient suppliers feeding US brands remain subject to preventive-controls registration under the FDA Food Safety Modernization Act. Dietary Supplements & Nutraceuticals brands, especially in Liquids & Shots and Capsules & Softgels, are absorbing the reformulation first, a pattern likely to persist through 2035 as GLP-1 prescribing continues.

Plant-Sourced Material Is Displacing Bovine Cortex Extraction

Health Canada’s NNHPD monograph, versioned January 2026, names only Helianthus annuus (sunflower seed) isolate and soy lecithin as accepted sources for its cognitive-function claim, formally excluding bovine cortex and porcine brain material from the pre-cleared route. Plant Source already holds 68% of supply. FAOSTAT records sunflower seed and soybean as globally traded oilseed crops, and the soy-derived lecithin used in these extracts is produced to the food-additive purity standards set by Codex Alimentarius. Buyers sourcing certified material increasingly specify EU organic regulation or USDA Organic status, and soy volumes moving into the European Union now carry EUDR deforestation-regulation traceability obligations back to the growing plot. Formulators serving Capsules & Softgels and Functional Foods categories built around the claim are converging on soy- and sunflower-derived material processed under HACCP-controlled extraction, a shift likely to compress Animal-derived share further as the claim regime spreads.

Divergent Claim Regimes Are Splitting North American and European Go-to-Market Strategy

Health Canada licenses a 300 mg per day cognitive-function claim for phosphatidylserine without a full submission, while EFSA’s 2010 opinion left the European Union without an authorized general-function cognitive claim, and any new source material would still need to clear EFSA’s novel food authorisation route before a claim could follow. Brand manufacturers respond with different playbooks: North American Capsules & Softgels SKUs carry the claim on pack under FDA labelling and nutrition-facts rules, while Western Europe and Eastern Europe formulations, constrained by EU Regulation 1169/2011 on food information to consumers, lean on ingredient presence alone. North American supplement growth is likely to keep outpacing EU functional food inclusion through 2035.

Segment Analysis

By Form

• Powder (largest) – A dry, encapsulation-ready form of phosphatidylserine derived from soy or sunflower lecithin, used in supplements, capsules, and functional food formulations

• Spray-Dried Powder
• Micronized Powder
• Granules
• Liquid – A fluid form of phosphatidylserine dissolved or suspended in oils or carriers, used in soft-gel fills, drops, and blended nutritional beverages

• Emulsion
• Oil Suspension
• Solution/Concentrate

By End Use

• Functional Foods – Everyday food and beverage products, such as fortified dairy, cereals, and drinks, into which phosphatidylserine is incorporated to support brain and cognitive health claims

• Fortified Dairy Products
• Bakery & Confectionery
• Beverages
• Infant Formula
• Fortified Snacks
• Dietary Supplements & Nutraceuticals – Capsules, softgels, tablets, and powders delivering concentrated phosphatidylserine doses aimed at memory, stress response, and cognitive support use cases
• Capsules & Softgels

• Softgel Capsules
• Hard-Shell Capsules

• Tablets
• Powders
• Liquids & Shots
• Gummies
• Cosmetics & Personal Care – Skincare and personal care formulations, including creams and serums, that use phosphatidylserine as a lipid ingredient for skin barrier and cell membrane support
• Skin Care

• Creams & Lotions
• Serums

• Hair Care
• Anti-Aging Formulations

Fortified dairy, beverage and infant-formula SKUs built on phosphatidylserine carry brain-health claims that fall under FDA labelling and nutrition-facts rules in the US and EU Regulation 1169/2011 on food information to consumers in Europe, where the ingredient itself entered the market through EFSA novel food authorisation. Codex Alimentarius purity and identity specifications provide the reference standard both regions build labelling enforcement around. That compliance load sits heaviest on functional-food formulators, since a cognitive-health claim on a cereal box invites more regulatory scrutiny than the same claim on a capsule label.

By Grade

• Food Grade – Purified phosphatidylserine manufactured to food-safety purity standards for use as a nutraceutical ingredient in dietary supplements, functional foods, and beverages

• Non-GMO Food Grade
• Soy-Derived Food Grade
• Sunflower-Derived Food Grade
• Pharmaceutical Grade (largest, 55% share) – Highly purified phosphatidylserine meeting drug-manufacturing quality and purity standards for use in prescription formulations and clinical-grade therapeutic products

• Injectable Grade
• Oral Dosage Grade
• GMP-Certified Grade

Pharmaceutical Grade led the market in 2025 with 55% of revenue. Pharmaceutical-grade phosphatidylserine meets GMP and drug-manufacturing purity standards required for prescription and clinical-grade cognitive-support formulations, a specification tier that commands a purity premium buyers in regulated therapeutic channels cannot substitute away from. Food Grade is growing faster as mainstream capsule, powder and gummy supplement brands scale volume. These plants operate under the FDA Food Safety Modernization Act’s preventive-controls rule and HACCP-based process control rather than pharmaceutical GMP, and shifting sourcing toward that lighter food-grade compliance tier lowers ingredient cost per SKU without sacrificing the cognitive-health claim.

By Nature

• Organic – Phosphatidylserine derived from raw materials such as soy or sunflower grown without synthetic pesticides or fertilizers, certified for use in clean-label supplements and foods

• Soy-based
• Sunflower-based
• Conventional (largest, 60% share) – Phosphatidylserine manufactured from standard soy or bovine cortex sources using traditional extraction methods without organic certification requirements

• Soy-based
• Sunflower-based
• Cabbage-based
• Bovine Cortex-derived

Conventional phosphatidylserine held 60% of the market in 2025, sourced from standard soy or bovine-cortex extraction without organic certification. Conventional material remains dominant because certification under the EU organic regulation or USDA Organic standard requires a verified, pesticide-free supply chain that raises input cost, and most functional-food and mass-supplement formulators do not yet need it to support a cognitive-health claim. Organic phosphatidylserine is growing faster, pulled by clean-label reformulation across supplement and functional-food brands seeking dual EU- and USDA-certified soy sourcing to differentiate premium SKUs on retail shelf.

By Source

• Plant Source (largest, 68% share) – Phosphatidylserine derived from botanical raw materials such as soy lecithin or sunflower lecithin through enzymatic conversion, used as a non-animal ingredient in supplements and functional foods

• Soybean
• Sunflower
• Others (Cabbage etc.)
• Animal-derived – Phosphatidylserine extracted from animal tissue sources such as bovine cortex, historically used in early formulations before soy and sunflower alternatives became common

• Bovine Cortex-derived
• Porcine Brain-derived

Plant Source phosphatidylserine, derived from soy or sunflower lecithin, held 68% of the market in 2025. Enzymatic conversion from soy and sunflower lecithin avoids the animal-tissue supply constraints and consumer resistance tied to bovine-cortex extraction, and delivers a non-animal ingredient claim increasingly required by supplement brands. Animal-derived material, the category’s original source, is receding as soy- and sunflower-based conversion capacity expands. Soy is also a named commodity under the EU’s deforestation regulation, EUDR, so European buyers of soy-derived phosphatidylserine now need traceable, deforestation-free sourcing documentation, a requirement sunflower-derived material sidesteps and one reason sunflower sourcing is pulling share from bovine cortex among brands seeking non-GMO, allergen-flexible positioning.

Regional Analysis

North America carries no disclosed regional share. Health Canada’s NNHPD monograph, updated January 2026, pre-clears a cognitive-support claim for phosphatidylserine at 300 mg daily, naming sunflower-isolate and soy-enriched sources as accepted routes. The United States is projected to grow at a 5.6% CAGR through 2035, with GLP-1-linked muscle-preservation positioning, flagged by an October 2025 consumer survey, opening new supplement formats.

Europe carries no disclosed regional share either. Lipoid is committing a triple-digit-million-euro sum to a phospholipid production and laboratory complex at its Cologne site, spanning over 15,000 square metres and due for commissioning in 2026. The United Kingdom leads regional growth at a 5.8% CAGR to 2035, ahead of France at 5.2% and Germany at 4.7%.

East Asia is the market’s named fastest-growing region, anchored by Japan at a 6.7% CAGR through 2035. South Korea’s MFDS recognised 45 functional-ingredient applications in 2022, double the prior year, widening the approval channel phosphatidylserine competes through since Doosan’s 2008 individually-approved cognitive-function listing established the category domestically.

Phosphatidylserine reaches Middle Eastern and African consumers mainly through imported supplement brands, since regional pharmaceutical-grade manufacturing capacity is limited. Modernizing pharmacy and hypermarket retail across Gulf states is the primary channel opening for cognitive-health positioning, ahead of any domestic processing base.

Latin America’s supply chain connects to the region’s position as a major global soy exporter, with Brazilian soy lecithin feeding plant-derived extraction upstream of finished-dose manufacturing elsewhere. Domestic demand remains concentrated in urban supplement retail rather than functional-food fortification.

Country Growth Comparison

A 2.0 point gap separates Japan at 6.7% from Germany at 4.7%.

Competitive Landscape

The Phosphatidylserine Market is moderately consolidated. Competition centers on purification technology and certification: pharmaceutical-grade GMP status, non-GMO and organic certification, and bio-conversion processes meeting regulatory purity thresholds without acetone or nucleic-acid-based refining steps, alongside procurement scale over soy and sunflower lecithin feedstock and distribution reach into supplement, functional-food and pharmaceutical formulators. No top-five share concentration is disclosed; the market is led by a group of established suppliers: Lonza Group, Enzymotec Ltd, Lipogen Products Ltd., Doosan Corporation, Novastell, Nagase ChemteX Corporation, Bontac Bio-engineering Co. Ltd., ECA Healthcare, Inc., Lipoid GmbH and Chemi Nutra LLC.

Lipoid is building a phospholipid production and laboratory complex at its Cologne site, a triple-digit-million-euro commitment spanning over 15,000 square metres, with a construction milestone reached in August 2025 and commissioning planned for 2026. In May 2022, Solus Biotech developed a high-purity phosphatidylserine grade delivering Korea’s MFDS-recognised 300 mg daily cognitive dose in a single capsule, tightening the purification bar competitors must match.

Strategic Outlook

The clearest whitespace sits in food-grade, plant-sourced phosphatidylserine formulated into mass-market capsules and gummies rather than pharmaceutical dosage forms. Soy-derived SKUs now carry an added compliance step: EU deforestation regulation (EUDR) traceability once shipments cross into the bloc, so suppliers able to document plot-level origin hold an edge on shelf listings. Formulators serving GLP-1-linked muscle-preservation and mood positioning stand to benefit most, provided non-soy sources gain a clean pathway through FDA’s GRAS review, the same 2016 withdrawals that still block bovine-cortex analogues, and clear EFSA’s novel food authorisation on the European side. Pack claims must satisfy FDA’s labelling and nutrition-facts rules and, for EU-bound stock, the food information requirements set out in EU Regulation 1169/2011.

By 2035, sourcing is expected to tilt further toward plant-derived, non-GMO material as bovine-cortex extraction recedes. HACCP-certified processing lines and ingredient specifications benchmarked to Codex Alimentarius are becoming the baseline for export eligibility, not a differentiator. Regulatory channels in East Asia and Canada are likely to keep setting the pace for new cognitive-health claims, pulling capacity investment toward markets with a pre-cleared route.

Phosphatidylserine Market Report Scope